Enlivex Therapeutics (ENLV, Financial) has successfully concluded patient enrollment for the Phase II segment of its clinical trial evaluating Allocetra's impact on moderate to severe knee osteoarthritis. This stage of the trial involved the randomization and treatment of 133 patients in a controlled and blinded setup.
The completion of this phase marks a key milestone for the company, which aims to deliver initial topline data by August 2025. This follows encouraging initial results from the earlier Phase I trial. Enlivex is optimistic about Allocetra's transformative potential in osteoarthritis treatment, a sentiment echoed by CEO Oren Hershkovitz.
As the company advances with its timeline, the forthcoming data release will be a significant event to watch for stakeholders and the broader medical community evaluating innovative solutions in osteoarthritis care.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Enlivex Therapeutics Ltd (ENLV, Financial) is $10.00 with a high estimate of $13.00 and a low estimate of $7.00. The average target implies an upside of 1,062.79% from the current price of $0.86. More detailed estimate data can be found on the Enlivex Therapeutics Ltd (ENLV) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Enlivex Therapeutics Ltd's (ENLV, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
